BioSpace News Archive

Servier, an independent global pharmaceutical group, has announced its financial results for the 2021/22 financial year and highlighted the major steps of its ongoing transformation.

Sensorion is pleased to announce its participation, in-person, in the Association for Research in Otolaryngology 46th Annual MidWinter Meeting, taking place on February 11-15, 2023, in Orlando, Florida, United States.

Anaveon, a clinical stage, immuno-oncology company, announced the first patient has been dosed in the OMNIA-1 study – a Phase I/II study assessing the efficacy and safety of ANV419 for the treatment of advanced melanoma.

Bronwyn Brophy is appointed as new CEO of Vitrolife AB (publ). She will join the company at the latest of 1 August 2023.

Spago Nanomedical initiated a Phase IIa clinical trial with SpagoPix in patients with suspected endometriosis, a chronic, debilitating condition that affects up to 10% of women of reproductive age.

Biophytis SA, a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, released the final results from its phase 2-3 COVA clinical study evaluating Sarconeos in the treatment of COVID-19-related respiratory failure.

Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, announced its business update and Year-end report for January to December 2022.

Calliditas Therapeutics AB announced that the Medicines and Healthcare products Regulatory Agency of the United Kingdom has granted Conditional Marketing Authorization for Kinpeygo® for the treatment of primary immunoglobulin A nephropathy in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio ≥1.5 g/gram.

Anton Hoos, M.D., Ph.D., MBA will become Head of R&D and Medical Affairs and Chief Medical Officer and replace Anders Ullman, M.D., Ph.D. who will retire.

Agomab Therapeutics NV announced positive clinical results from its Phase 1 study evaluating AGMB-129, an oral gastro-intestinal -restricted small molecule kinase inhibitor of ALK5, intended for the treatment of Fibrostenosing Crohn’s Disease.